| ²é¿´: 1499 | »Ø¸´: 3 | |||||
»ªÎ÷ÎàÍ©Ê÷Òø³æ (ÕýʽдÊÖ)
|
[½»Á÷]
Å·ÖÞ ÂêÀö¾ÓÀアѧ½ð ÑÛ²¿¸øÒ©²©Ê¿¸ÚλÕÐÆ¸ ÒÑÓÐ3È˲ÎÓë
|
|
Fifteen Early Stage Researcher (ESR) vacancies in the Marie Sklodowska-Curie Innovative Training Network http://www.uef.fi/web/ocuther-eu/vacancies ÏêÇé¿ÉÒÔ×Ô¼ºÈ¥¿´ÁË¡£ Kinetic modelling of drugs and nanocarriers in the posterior eye segment; University of Eastern Finland (Finland) ESR2: Profiling of ADME properties of drug candidates and retinal cells models; University of Eastern Finland (Finland) ESR3: Pathogenesis of age-related macular degeneration (AMD); University of Eastern Finland (Finland) ESR4: Effects of sustained delivery of VCP inhibitors in animal models of retinitis pigmentosa; Eberhard- Karls-University, T¨¹bingen (Germany) ESR5: Effects of intravitreal slow controlled release of neurotrophic retinal M¨¹ller glial cell (RMC)-derived factors; Eberhard-Karls-University, T¨¹bingen (Germany) ESR6: Ocular response to Nanoparticles to be used for intraocular drug delivery; Queen¡¯s University Belfast (UK) ESR7: Sustained intraocular drug delivery for the management of inflammation induced retinal angiogenesis; Queen¡¯s University Belfast (UK) ESR8: Non-invasive pharmacological treatment of retinal degeneration in the Bardet-Biedl Syndrome and related ciliopathies (University of Strasbourg, France) ESR9: Protein cages modified for cell selective delivery of siRNA to retinal cells; Eindhoven University of Technology (TU/e, The Netherlands) ESR10: Supramolecular bioconjugates for ocular delivery; University of Padova (Italy) ESR11: Multifunctional colloidal formulations for ocular delivery; University of Padova (Italy) ESR12: Development of sustained release formulations for ocular delivery; Utrecht University (The Netherlands) ESR13: Focused ultrasound (FUS) in ocular drug delivery; Utrecht University/University Medical Centre Utrecht Utrecht, The Netherlands) ESR14: Magnetic Nanoparticles for Retinal Delivery; OZ Biosciences (OZB) (France) ESR15: Development of a physiologically based systems pharmacology model of the eye; Simcyp (UK) |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
Áôѧ | »ù½ðÓë¼Æ»® |
» ²ÂÄãϲ»¶
΢Äɼӹ¤É豸
ÒѾÓÐ0È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÑо¿×éÕÐÊÕ²©Ê¿Éú
ÒѾÓÐ1È˻ظ´
°ëµ¼Ìå¿ÆÑ§ÓëÐÅÏ¢Æ÷¼þÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ115È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÍŶÓÕÐÆ¸½ÌʦºÍ²©Ê¿ºó
ÒѾÓÐ0È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÍŶÓÕÐÊÕ²©Ê¿Éú
ÒѾÓÐ0È˻ظ´
Ìì½òÀí¹¤´óѧ-¹ú¼Òº£ÍâÓÅÇຫ¾Ã»Û½ÌÊÚ-26Ä격ʿÕÐÉú-²ÄÁÏ¡¢»¯Ñ§µÈÁìÓò
ÒѾÓÐ0È˻ظ´
2026°ëµ¼ÌåÆ÷¼þ²©Ê¿ÉêÇë
ÒѾÓÐ0È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÍŶÓÕÐÊÕ²©Ê¿Éú
ÒѾÓÐ0È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÍŶÓÕÐÊÕ²©Ê¿Éú
ÒѾÓÐ0È˻ظ´
ÉϺ£½»Í¨´óѧ¼¯³Éµç·ѧԺÄÉÃ×µç×Ӻ͹âµçÆ÷¼þÍŶÓÕÐÆ¸½ÌʦºÍ²©Ê¿ºó
ÒѾÓÐ0È˻ظ´

wzarlll
гæ (ÖøÃûдÊÖ)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 9024.5
- É¢½ð: 2514
- ºì»¨: 18
- Ìû×Ó: 1312
- ÔÚÏß: 657.6Сʱ
- ³æºÅ: 1300638
- ×¢²á: 2011-05-19
- ÐÔ±ð: GG
- רҵ: °ëµ¼Ìå¹âµç×ÓÆ÷¼þ
2Â¥2017-01-04 18:07:55
ľéÈľ×Ó
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1535.3
- ºì»¨: 1
- Ìû×Ó: 164
- ÔÚÏß: 109Сʱ
- ³æºÅ: 4022098
- ×¢²á: 2015-08-14
- רҵ: Éñ¾ÉúÎïѧ
3Â¥2017-01-10 09:16:43
gnehzus924
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 3065.1
- É¢½ð: 63
- ºì»¨: 7
- Ìû×Ó: 448
- ÔÚÏß: 208Сʱ
- ³æºÅ: 1141990
- ×¢²á: 2010-11-08
- ÐÔ±ð: GG
- רҵ: ¹Ç¡¢¹Ø½Ú¡¢Èí×éÖ¯¸ÐȾ
4Â¥2018-02-14 16:37:30













»Ø¸´´ËÂ¥

